Medical Role of Pabrinex Injection 1 and 2
Pabrinex is a high-dose intravenous water-soluble B-vitamin complex with vitamin C used primarily for rapid correction of severe vitamin deficiencies in patients who cannot absorb or tolerate oral supplementation, particularly in critical illness, chronic alcoholism, malabsorption syndromes, and conditions requiring urgent vitamin repletion.
Primary Clinical Indications
Critical Illness and Acute Inflammatory States
During critical illness, IV administration of water-soluble vitamins becomes essential because enteral absorption is unreliable due to impaired gut function and the saturable nature of enteral transporters 1. In critically ill patients with acute inflammation (sepsis, trauma, major surgery, cardiac arrest), vitamin C repletion doses of 2-3 g/day IV should be administered during the acute inflammatory phase 1. Plasma vitamin C concentrations decline rapidly in these conditions and are associated with severity of oxidative stress, organ failure, and mortality 1.
Chronic Conditions with Oxidative Stress
For patients with chronic oxidative stress states including:
- Diabetes mellitus
- Heart failure
- Severe COPD
- Chronic dialysis (including CRRT)
- Chronic alcoholism
- Active smoking
A dose of 200-500 mg/day of vitamin C may be provided 1. These conditions are associated with high risk of vitamin depletion due to enhanced metabolic demands.
Malabsorption Syndromes
In patients with chronic malabsorption (short bowel syndrome, cystic fibrosis, coeliac disease, chronic diarrhea), IV vitamin supplementation prevents deficiency when oral absorption is compromised 1. Fat-soluble vitamin A deficiency may also occur in these conditions, though IV retinol palmitate data remains insufficient for firm recommendations 1.
Specific Dosing Contexts
Parenteral Nutrition
Standard PN doses include vitamin C 100-200 mg/day 1. However, during critical illness with prolonged hypermetabolic conditions, higher repletion doses are required as outlined above.
Perioperative Use
For cardiac surgery patients, periprocedural vitamin C repletion of 1-2 g/day IV for 5-7 days carries Grade 1+ evidence 1.
Suspected Scurvy
When clinical symptoms suggest scurvy or chronic low vitamin C intake, do not delay a clinical trial of approximately 1 g/day vitamin C for at least one week while awaiting laboratory confirmation 1. Plasma vitamin C measurement is appropriate in these cases but should not delay treatment.
Important Caveats
Inflammation Effects on Monitoring
Do not measure plasma vitamin C in critical illness or severe inflammation for monitoring purposes - interpretation is unreliable because levels decline rapidly when CRP >10 mg/L, and normal values are not detected when CRP >40 mg/L 1. The decline reflects enhanced metabolic demands rather than true tissue depletion.
Administration Considerations
- IV route is mandatory in critical illness - enteral uptake is unpredictable 1
- Dilute with normal saline or glucose to minimize adverse reactions 1
- Vitamin A in PN is light-sensitive and requires light-protecting materials; monitor periodically in long-term PN due to photo-degradation and adsorption losses 1
- Sustained therapy is needed to prevent recurrence of hypovitaminosis 1
Evidence Limitations
While low plasma vitamin C is associated with poor outcomes in critical illness, whether correcting plasma concentrations during severe inflammation improves mortality or morbidity remains unknown and requires further research 1. The optimal dose during critical illness is not definitively established, though the ranges above represent current best evidence.
Practical Algorithm
Identify the clinical scenario:
- Critical illness with inflammation (sepsis, trauma, surgery, cardiac arrest) → 2-3 g/day IV
- Chronic oxidative stress conditions (diabetes, heart failure, COPD, dialysis, alcoholism) → 200-500 mg/day
- Malabsorption syndromes → IV route with doses as above based on severity
- Suspected scurvy → 1 g/day for ≥1 week, do not delay for labs
- Cardiac surgery → 1-2 g/day for 5-7 days perioperatively
Route selection: IV mandatory in critical illness; IM/IV acceptable in malabsorption; oral ineffective when gut function compromised
Duration: Sustained therapy during acute phase; reassess as inflammation resolves